Investors

Press Releases

Press Releases

Date Title View
Toggle Summary Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) International Conference 2019
To include highlights of the safety and tolerability of LIQ861 at two months of treatment in the INSPIRE Phase 3 Trial RESEARCH TRIANGLE PARK, N.C. , May 14, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company, today
View HTML
Toggle Summary Liquidia Technologies Reports First Quarter 2019 Financial Results and Provides Corporate Update
Recent Phase 3 Data Highlight Clinical Relevance of LIQ861 in Treating P ulmonary Arterial Hypertension On Track for Planned New Drug Application (NDA) Submission for LIQ861 in Late 2019 Continued Pipeline Progress Leveraging Proprietary Print® Technology Management to Host Webcast and Conference
View HTML
Toggle Summary Liquidia Technologies to Report First Quarter 2019 Financial Results and Provide Corporate Update on May 2, 2019
RESEARCH TRIANGLE PARK, N.C. , April 23, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”),  a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Presents Phase 3 Trial Data for LIQ861 at the ISHLT 39th Annual Meeting & Scientific Sessions
Positive Data from INSPIRE Trial Continues to Highlight Safety and Tolerability Along with Improvement in Quality of Life Metrics from LIQ861 RESEARCH TRIANGLE PARK, N.C. , April 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA) (“Liquidia”), a late-stage clinical
View HTML
Toggle Summary Liquidia Technologies to Present at Needham Healthcare Conference
RESEARCH TRIANGLE PARK, N.C. , April 02, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”) , a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Closing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Pricing of Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 21, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia Technologies Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C. , March 18, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the
View HTML
Toggle Summary Liquidia’s LIQ861 Meets Primary Endpoint in Pivotal Phase 3 INSPIRE Study in Patients with Pulmonary Arterial Hypertension
•  LIQ861 was well-tolerated in PAH patients at two months of treatment •  INSPIRE enrollment complete, including PK sub-study •  Anticipate submitting NDA for LIQ861 to the FDA in late 2019 RESEARCH TRIANGLE PARK, N.C. , March 11, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc.
View HTML
Toggle Summary Liquidia Technologies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Reported positive interim LIQ861 safety data from its pivotal Phase 3 INSPIRE clinical trial Accepted by FDA into Emerging Technology Program to support review of PRINT ® technology Management to host webcast and conference call today at 8:00 a.m. ET RESEARCH TRIANGLE PARK, N.C. , Feb.
View HTML